Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients
Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability and efficacy of Raltegravir (RAL) when combined with other
antiretroviral drugs in treatment-experienced Chinese HIV-infected patients, including those
with multi-drug resistant HIV-1 infection or drug intolerance.